v3.25.2
Operating Segments - Segment Revenues and Profit (Loss) (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment reporting          
Number of operating segments | segment       2  
Revenues     $ 2,342   $ 119,371
Cost of revenues     (2,342)   (119,371)
Research and development $ 1,677,014 $ 1,941,680 501,158 $ 3,618,694 1,596,198
General and administrative 1,086,865   1,243,517 2,171,693 2,265,568
Adjusted loss from operations (2,763,879)   (1,744,675) (5,790,387) (3,861,766)
Share-based compensation       163,112 117,636
Loss from operations (2,763,879) $ (3,026,508) (1,744,675) (5,790,387) (3,861,766)
Other (expenses) income, net 61,903   100,173 137,143 301,937
Net loss before income taxes (2,701,976)   (1,644,502) (5,653,244) (3,559,829)
Total Segments          
Segment reporting          
Revenues     2,342   119,371
Cost of revenues     (2,342)   (119,371)
Research and development 1,526,431   322,589 3,335,368 1,206,818
Adjusted loss from operations (1,526,431)   (322,589) (3,335,368) (1,206,818)
Share-based compensation 27,326   21,557 54,654 42,817
Depreciation and amortization 493   1,112 918 2,224
Loss from operations (1,554,250)   (345,258) (3,390,940) (1,251,859)
Other (expenses) income, net     (31,346)   (23,806)
Net loss before income taxes (1,554,250)   (376,604) (3,390,940) (1,275,665)
Total Segments | Specialized BioTherapeutics          
Segment reporting          
Revenues     2,342   119,371
Cost of revenues     (2,342)   (119,371)
Research and development 1,523,099   261,313 3,273,701 1,100,292
Adjusted loss from operations (1,523,099)   (261,313) (3,273,701) (1,100,292)
Share-based compensation 26,487   20,940 52,975 41,612
Depreciation and amortization 423   953 787 1,906
Loss from operations (1,550,009)   (283,206) (3,327,463) (1,143,810)
Other (expenses) income, net     (31,346)   (23,806)
Net loss before income taxes (1,550,009)   (314,552) (3,327,463) (1,167,616)
Total Segments | Public Health Solutions          
Segment reporting          
Research and development 3,332   61,276 61,667 106,526
Adjusted loss from operations (3,332)   (61,276) (61,667) (106,526)
Share-based compensation 839   617 1,679 1,205
Depreciation and amortization 70   159 131 318
Loss from operations (4,241)   (62,052) (63,477) (108,049)
Net loss before income taxes (4,241)   (62,052) (63,477) (108,049)
Adjustments          
Segment reporting          
Research and development 27,819   22,669 55,572 45,041
Adjusted loss from operations (27,819)   (22,669) (55,572) (45,041)
Share-based compensation (27,326)   (21,557) (54,654) (42,817)
Depreciation and amortization (493)   (1,112) (918) (2,224)
Corporate          
Segment reporting          
Research and development 122,764   155,900 227,754 344,339
General and administrative 1,014,468   1,206,923 2,062,842 2,189,797
Adjusted loss from operations (1,137,232)   (1,362,823) (2,290,596) (2,534,136)
Share-based compensation 72,187   36,118 108,458 74,819
Depreciation and amortization 210   476 393 952
Loss from operations (1,209,629)   (1,399,417) (2,399,447) (2,609,907)
Other (expenses) income, net 61,903   131,519 137,143 325,743
Net loss before income taxes (1,147,726)   (1,267,898) (2,262,304) (2,284,164)
Adjustments.          
Segment reporting          
General and administrative 72,397   36,594 108,851 75,771
Adjusted loss from operations (72,397)   (36,594) (108,851) (75,771)
Share-based compensation (72,187)   (36,118) (108,458) (74,819)
Depreciation and amortization $ (210)   $ (476) $ (393) $ (952)